Effects of intravenous thrombolysis with alteplase combined with edaravone on cerebral hemodynamics and T lymphocyte level in patients with acute cerebral infarction

Abstract

Our study aimed to investigate the effect of intravenous thrombolysis with alteplase and edaravone on cerebral hemodynamics and T lymphocyte level in patients harboring acute cerebral infarction. There involved a total of 118 patients with acute cerebral infarction from November 2017 to May 2019 in our hospital were randomly divided into 2 groups: the observation group (59 patients were treated with intravenous thrombolysis with alteplase combined with edaravone) and the control group (59 patients were treated with intravenous thrombolysis of alteplase). The clinical effect, neurological function, cerebral hemodynamic index, T lymphocyte level, oxygen free radical scavenging level and oxidative stress index of the 2 groups were observed and compared. Before the treatment, there were no significant differences in neurological function, cerebral hemodynamic indexes, T-lymphocyte level, oxygen free radical scavenging level and oxidative stress indexes between the 2 groups ( P > .05). After the treatment, the neurological function, cerebral hemodynamic indexes, T-lymphocyte level, oxygen free radical scavenging level and oxidative stress indexes of the 2 groups were significantly improved. In addition, the observation group exerted greater beneficial effect in terms of the clinical effect, neurologic function, cerebral hemodynamic index, T lymphocyte level, oxygen free radical scavenging level and oxidative stress index than those of the control group ( P < .05). The intravenous thrombolysis with alteplase and edaravone is effective in the treatment of acute cerebral infarction, which also provides better results in terms of improving the clinical efficacy and prognosis of patients and might be an alternative option for clinical practice.

Edaravone Combined with Clopidogrel Is Beneficial to Improve Efficacy, Neurological Impairment, and Life Function in Acute Cerebral Infarction Patients

“…e efficacy of the two groups was observed and counted after treatment [15]: according to NIHSS results, it is divided into four degrees: cure, remarkably effective, effective, and ineffective as follows: cure: the NIHSS score decreases by more than 90%, and clinical symptoms such as dizziness basically disappear; remarkably effective: the NIHSS score is reduced by 46%-90, and the clinical symptoms such as dizziness are obviously relieved; effective: the NIHSS score is reduced by 18%-45%, and clinical symptoms such as vertigo are slightly relieved; ineffective: the NIHSS score and clinical symptoms are not dramatically improved or even aggravated. Total effective rate � (cure + remarkably effective + effective)/total number.…”

CT perfusion imaging parameters and serum miR-106a-5p predict short- and long-term prognosis in acute cerebral infarction patients after intravenous thrombolysis

“…Thrombolysis can be administered within 6 hours after the onset of ACI, and reperfusion of the originally ischemic cells of cerebral nervous tissue by intravenous administration of thrombolysis can effectively restore cerebral blood flow perfusion and reduce the degree of neurological damage. [2,3] Even so, patients experience poor outcomes after undergoing acute phase thrombolysis. [2] Therefore, early and accurate examination and prognostic evaluation are important means to choose the right treatment option clinically.…”

Clinical Efficacy Evaluation and Potential Mechanism of Zhishe Tongluo Capsule in the Treatment of Cerebral Infarction by Meta-Analysis Associated with Network Pharmacology

“…According to the statistics, when it becomes available to approximately 55.5 million people every year worldwide without receiving timely treatment, infarct in the anterior bulb is currently a global concern [ 1 , 2 ], and studies of this disease have shown that the morbidity and mortality of the disease are submaximal in Asia [ 3 ], especially in China and Eastern Europe. In addition, according to the mainland burden report, if the incidence of cerebral infarction does not change, the total number of deaths from cerebral infarction will reach more than 30% in 2035 [ 4 , 5 ]. Infarct is fast and severe, and long-term care is required for the treatment, the incidence of cerebral infarction is fast and harmful, and the long-term care is required for the treatment follow-up [ 6 ], in which social development greatly imposes a large burden on socioeconomic development [ 7 ].…”